Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
About this study
The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.
- Condition
- Colorectal Cancer
- Tested
- Observation
- Sponsor
- Tempus AI
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 18 years
- Study condition: Colorectal Cancer
- Known or suspected colorectal adenocarcinoma (Stage I to IVA disease)
- Planning to undergo or has undergone a surgical resection for suspected adenocarcinoma of the colon or rectum with curative intent.
- 18 years old or older
- Willing and able to provide informed consent
- Willing to have additional blood samples collected during routine surveillance visits
Exclusion 2
- Not willing to have additional blood samples collected
- Pathology that is not consistent with colorectal adenocarcinoma
Where
20 sites, 20 recruiting
ThedaCare Regional Cancer Center
Appleton, Wisconsin, United States
The Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
Aultman Hospital
Canton, Ohio, United States
TriHealth Cancer Institute
Cincinnati, Ohio, United States
Ohio State University
Columbus, Ohio, United States
OhioHealth Research Institute
Columbus, Ohio, United States
and 14 more sites on ClinicalTrials.gov
Contact
-
CRC Surveillance Study
(833) 514-4187 gemini-crc@tempus.com
Potential match only. Final eligibility is determined by the study team.